FDA Inspection 1272748 — 3D Imaging Drug Design and Development LLC
The FDA completed an inspection of 3D Imaging Drug Design and Development LLC on June 13, 2025 in Little Rock, AR. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- June 13, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Little Rock, AR (United States)